9/2/2023 0 Comments Pradaxa antidote![]() ![]() ![]() This gives a quantitative estimate of dabigatran levels. The Hemoclot test is also available in some centres.Dabigatran is contraindicated in patients with severe kidney impairment (creatinine clearance 80 seconds is associated with a higher bleeding risk.Kidney function should be assessed in all patients prior to beginning dabigatran therapy.*Prescribers should note that these are contraindications Kidney function testingĪs dabigatran is primarily excreted renally, one of the risk factors for bleeding is having moderate kidney impairment (creatinine clearance 30–50 mL/min).īelow is a summary of the recommendations for assessing kidney function before starting dabigatran: Active ulcerative gastrointestinal disease.Thrombocytopenia or functional platelet defects.Congenital or acquired coagulation disorders.Non Steroidal Anti-inflammatory Drugs (NSAID)ĭiseases / procedures with special haemorrhagic risks*.Selected P-glycoprotein-inhibitor co-medication.Moderate renal impairment (30–50 mL/min CrCL).Ageįactors increasing dabigatran plasma levels Factors known to increase the risk of bleedingįactors known to increase the bleeding risk are outlined in the below table and can also be found in the Precautions section of the PI. ![]() Prescribers should continually review all patients for signs of bleeding and anaemia, in particular, those with risk factors. Prescribers are advised that there appears to be a trend towards a higher incidence of major bleeds in patients aged 75 years or over taking dabigatran 150 mg twice daily compared to warfarin 1 (see ' Other important considerations'). Prescribers are urged to give careful consideration to the suitability of their patients for dabigatran, particularly with regard to the risks of bleeding and their current stability on warfarin or other anticoagulants. It is strongly recommended that prescribers read the Product Information (PI) before prescribing dabigatran. The TGA reviews have reinforced the importance of appropriate patient selection to enhance the safe use of dabigatran. In this section: Factors known to increase the risk of bleeding | Kidney function testing | Other important considerations | Laboratory tests for dabigatran On this page: Information for health professionals | Additional information | International regulators | Reporting problems | References Information for health professionals
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |